Corcept Therapeutics’ Post

Checkout the 8th article of "Life Takes Guts" newsletter Hope On the Horizon: Exciting Research Advances in IBD Care and Treatment #IBD #CrohnsDisease #UlcerativeColitis #IBDresearch #IBDtreatment #healthcare #medicalresearch

Even with considerable progress in the development of new therapies, there’s no real sign that steroid use is declining. In fact, several recent studies show that usage is actually on the rise. 📈 We explored with John Stone, MD MPH why this may be the case, particularly with the known effects of #steroidtoxicity. https://hubs.li/Q01-yfbz0 #SteritasGTI #Rheumatology #InConversation #Healthcare #PatientCare

Even with considerable progress in the development of new therapies, there’s no real sign that steroid use is declining. In fact, several recent studies show that usage is actually on the rise. 📈 We explored with John Stone, MD MPH why this may be the case, particularly with the known effects of #steroidtoxicity. https://hubs.li/Q01-yg1r0 #SteritasGTI #Rheumatology #InConversation #Healthcare #PatientCare

In a recently published article by Awa Diop and colleagues in “Statistical Methods in Medical Research” journal, a new novel two-step approach in Latent Class Growth Analysis (LCGA) and Marginal Structural Model (MSM) is introduced. Here, we captured the dynamic medication adherence patterns of Statin for primary prevention of cardiovascular events in older adults using RWD from Quebec. There were four distinct groups with similar treatment patterns that could be classified under our LCGA MSM approach.    At CCS, we are excited to add this new novel method into our toolbox. This specific tool will allow for better understanding of medication adherence and the corresponding patient characteristics and their association with treatment outcomes. Better understanding of dynamic nature of adherence is critical for drug development and management.    https://lnkd.in/eFwTkH3m  #statistics #causalinference #rwd

While high heart failure care costs in the U.S. are frequently reported, little is known about the specific cost contributors. A recent study led by DCRI Fellow Mark Kittipibul looks at cost differences for HF patients with ≤40% vs >40 ejection fraction, and how SGLT2i therapy could improve outcomes and reduce costs: https://lnkd.in/eikxyFXn #clinicalresearch #clinicaltrials #heartfailure #healthcarecosts

Publication of Patient-Reported Outcomes and Tolerability in GIST Patients Receiving Ripretinib versus Sunitinib in the Phase 3 INTRIGUE Study. Important new information for patients starting ripretinib treatment.

New from JN Learning: Clinical Practice Guideline for Transfusion Thresholds in Preterm Neonates https://lnkd.in/gYwj6cMX